Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00432770
Status:
COMPLETED
Last Update Posted:
2007-04-20
First Post:
2007-02-06
Brief Title:
Safety Pharmacokinetics and Pharmacodynamics of ARC1779 in Healthy Volunteers
Sponsor:
Archemix Corp
Organization:
Archemix Corp
Study Overview
Official Title:
A Phase 1 Single-Site Double-BlindRandomized Dose Escalation Study of the Safety Pharmacokinetics and Pharmacodynamics of Intravenous Bolus or Intravenous Bolus Followed by Continuous Infusion Administration of ARC1779 Compared to Placebo in Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish the overall safety and tolerability of ARC1779 in healthy volunteers and to characterize its pharmacokinetic and pharmacodynamic profile with respect to parameters of platelet function and von Willebrand Factor activity
Detailed Description:
The purpose of this study is to establish the overall safety and tolerability of ARC1779 in healthy volunteers and to characterize its pharmacokinetic and pharmacodynamic profile with respect to parameters of platelet function and von Willebrand Factor activity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None